The Design, Synthesis, and Antiviral Activity of Monofluoro and Difluoro Analogues of 4′-Azidocytidine against Hepatitis C Virus Replication: The Discovery of 4′-Azido-2′-deoxy-2′-fluorocytidine and 4′-Azido-2′-dideoxy-2′,2′-difluorocytidine

The discovery of 4′-azidocytidine (3) (R1479) ( J. Biol. Chem. 2006, 281, 3793 ; Bioorg. Med. Chem. Lett. 2007, 17, 2570 ) as a potent inhibitor of RNA synthesis by NS5B (EC50 = 1.28 μM), the RNA polymerase encoded by hepatitis C virus (HCV), has led to the synthesis and biological evaluation of sev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2009-05, Vol.52 (9), p.2971-2978
Hauptverfasser: Smith, David B, Kalayanov, Genadiy, Sund, Christian, Winqvist, Anna, Maltseva, Tatiana, Leveque, Vincent J.-P, Rajyaguru, Sonal, Pogam, Sophie Le, Najera, Isabel, Benkestock, Kurt, Zhou, Xiao-Xiong, Kaiser, Ann C, Maag, Hans, Cammack, Nick, Martin, Joseph A, Swallow, Steven, Johansson, Nils Gunnar, Klumpp, Klaus, Smith, Mark
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The discovery of 4′-azidocytidine (3) (R1479) ( J. Biol. Chem. 2006, 281, 3793 ; Bioorg. Med. Chem. Lett. 2007, 17, 2570 ) as a potent inhibitor of RNA synthesis by NS5B (EC50 = 1.28 μM), the RNA polymerase encoded by hepatitis C virus (HCV), has led to the synthesis and biological evaluation of several monofluoro and difluoro derivatives of 4′-azidocytidine. The most potent compounds in this series were 4′-azido-2′-deoxy-2′,2′-difluorocytidine and 4′-azido-2′-deoxy-2′-fluoroarabinocytidine with antiviral EC50 of 66 nM and 24 nM in the HCV replicon system, respectively. The structure−activity relationships within this series were discussed, which led to the discovery of these novel nucleoside analogues with the most potent compound, showing more than a 50-fold increase in antiviral potency as compared to 4′-azidocytidine (3).
ISSN:0022-2623
1520-4804
DOI:10.1021/jm801595c